Incyte's Immuno-oncology and Targeted Therapy Portfolio to be Featured at the AACR Annual Meeting 2016

WILMINGTON, Del.--(BUSINESS WIRE)--

Incyte Corporation INCY announces that ten abstracts featuring data from its emerging development portfolio will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana from April 16–20, 2016. These abstracts include data from the Company's monoclonal antibody agonist programs targeting GITR and OX40 as well as its small molecule inhibitor programs targeting LSD1, BRD (BET), PI3Kδ and JAK1.

"We are pleased to present the latest scientific data that underlie the potential of our emerging development portfolio at the upcoming AACR annual meeting," stated Reid Huber, PhD, Chief Scientific Officer, Incyte. "This collection of abstracts exemplifies our discovery team's innovative approach to cancer research, and reinforces Incyte's commitment to the advancement of novel therapeutics which have the potential to improve and extend the lives of patients living with cancer."

In addition to these presentations, Incyte has been invited to present "IDO1 Inhibition as a Modifier of the Immune Composition of the Tumor Microenvironment and a Component of Combination Immunotherapy for Cancer," as part of an AACR Major Symposia entitled, "Cancer Immunotherapy: Small Molecule Approaches" scheduled for Wednesday, April 20, 2016 from 10:15 a.m.–12:00 p.m., Ernest N. Morial Convention Center, Theater C, New Orleans, La.

Key abstract presentations, including Incyte-sponsored and independent investigator studies, include:

Effects of INCB052793, a Selective JAK1 Inhibitor, in Combination with Standard of Care Agents in Human Multiple Myeloma (MM) Cell Lines and Xenograft Models (Abstract #1339)

• Monday April 18, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 19

Preliminary safety, efficacy, and pharmacodynamics of a highly selective PI3Kδ inhibitor, INCB050465, in patients with previously treated B-cell malignancies (Abstract #CT056)

• Monday Apr 18, 2016 1:00–5:00 p.m., Halls G-J, Poster Section 13

INCAGN01949: An anti-OX40 agonist antibody with the potential to enhance tumor specific T cell responsiveness, while selectively depleting intratumoral regulatory T cells (Abstract #3204)

• Tuesday, April 19, 2016, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 25

A novel agonist antibody (INCAGN01876) that targets the co-stimulatory receptor GITR (Abstract #3220)

• Tuesday, April 19, 2016, 8:00 a.m. –12:00 p.m., Halls G-J, Poster Section 25

Activity of the BET Inhibitor INCB054329 in models of lymphoma (Abstract #3780)

• Tuesday, April 19, 2016, 1:00–5:00 p.m., Halls G-J, Poster Section 16

The LSD1 inhibitor INCB059872 is synergistic with ATRA in models of non-APL acute myelogenous leukemia (Abstract #4696)

• Wednesday, April 20, 2016, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 16

Combination of BET inhibitor INCB054329 and LSD1 inhibitor INCB059872 is synergistic for the treatment of AML in vitro and in vivo (Abstract #4702)

• Wednesday, April 20, 2016, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 16

The evaluation of INCB059872, an FAD-directed Inhibitor of LSD1, in preclinical models of human small cell lung cancer (Abstract #4704)

• Wednesday, April 20, 2016, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 16

Discovery of INCB059872, a novel FAD-directed LSD1 inhibitor that is effective in preclinical models of human and murine AML (Abstract #4712)

• Wednesday, April 20, 2016, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 16

The BET inhibitor INCB054329 enhances the activity of checkpoint modulation in syngeneic tumor models (Abstract #4904)

• Wednesday, April 20, 2016, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 23

Full session details for AACR 2016 can be found here.

Investor Event and Webcast

In addition, Incyte will host an investor event and webcast to discuss the data, science and strategy behind its emerging development portfolio at 7:00 p.m. CT on April 17, 2016. The webcast can be accessed at www.incyte.com under Investor Relations, Events and Presentations.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company's development pipeline and its presentation plans for the upcoming AACR annual meeting, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company's development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2015. Incyte disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160316006436/en/